✦ LIBER ✦

U.S. drug and biologic product approvals during 1993

✍ Scribed by John F. Beary III; C. Robert Eaton; Thomas L. Copmann; Dale E. Wierenga

Publisher: John Wiley and Sons
Year: 1994
Tongue: English
Weight: 485 KB
Volume: 32
Category: Article
ISSN: 0272-4391
DOI: 10.1002/ddr.430320302

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

U.S. drug and biologic approvals in 1996

✍ John F. Beary III; Lara E. Robillard; Gillian R. Woollett; John D. Siegfried; Th 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB 👁 1 views

Since the introduction of the Prescription Drug User Fee Act of 1992, the mean approval time for new drugs has decreased from 29.9 months (1992) to 17.8 months (1996).

U.S. drug and biologic approvals in 1994

U.S. drug and biologic approvals in 1994–1995

✍ John F. Beary III; Christina M. Duchaine; Reginald W. Rhein Jr. 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 784 KB

Since the introduction of the Prescription D r u g User Fee in 1992, the mean approval time for new drugs has decreased from 29.9 months (1992) t o 19.2 months (1995). In 1994, 22 new drugs and 1 biological were approved. In 1995, 28 drugs and 2 biologicals were approved.

US drug and biologic approvals in 1998

✍ Bert Spilker; Stacey FitzSimmons; Michael Horan 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB 👁 1 views

The Prescription Drug User Fee Act of 1992 enhanced review resources for the Food and Drug Administration (FDA). The past 3 years have seen an unprecedented approval of 122 new drugs and 28 new biologics. Information is provided on the 39 new products approved by the

US drug and biologic approvals in 1997

✍ John F. Beary III; John D. Siegfried; Renee Tavares 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 837 KB

The Prescription Drug User Fee Act of 1992 enhanced review resources for the Food and Drug Administration (FDA). The past two years have seen an unprecedented approval of 92 new drugs and 19 new biologics. Information is provided on the 49 new products approved by the FDA in 1997.

Prevalence and patterns of nitrosatable

Prevalence and patterns of nitrosatable drug use among U.S. women during early pregnancy

✍ Jean D. Brender; Katherine E. Kelley; Martha M. Werler; Peter H. Langlois; Lucin 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 672 KB

## BACKROUND Experimental evidence indicates that certain drugs, that are secondary or tertiary amines or amides, form __N__-nitroso compounds in the presence of nitrite in an acidic environment. Nitrosatable drugs have been associated with birth defects in a few epidemiologic studies. This study d

Acute stroke therapy with tissue plasmin

Acute stroke therapy with tissue plasminogen activator (tPA) since it was approved by the U.S. Food and Drug Administration (FDA)

✍ Justin A. Zivin 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB